日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis

MT-1186-A04 3b 期扩展研究旨在评估依达拉奉口服混悬液在肌萎缩侧索硬化症患者中持续 48 周的疗效和安全性

期刊:Muscle & Nerve
影响因子:3.1
doi:10.1002/mus.70120
Genge, Angela; Rothstein, Jeffrey; De Silva, Shari; Zinman, Lorne; Chum, Marvin; Chiò, Adriano; Sobue, Gen; Aoki, Masashi; Yoshino, Hiide; Doyu, Manabu; Selness, Daniel; Todorovic, Vesna; Hirai, Manabu; Sasson, Nissim; Takahashi, Fumihiro; Cecić, Michelle; Wamil, Art; Apple, Stephen
发表日期：2026
文献求助 收藏

Efficacy and Safety of Once Daily Dosing vs. Approved On/Off Dosing of Edaravone Oral Suspension Up to 48 Weeks in Patients With Amyotrophic Lateral Sclerosis (Study MT-1186-A02)

肌萎缩侧索硬化症患者每日一次给药与批准的间歇性给药方案（依达拉奉口服混悬液）长达 48 周的疗效和安全性比较（MT-1186-A02 研究）

期刊:Muscle & Nerve
影响因子:3.1
doi:10.1002/mus.28448
Rothstein, Jeffrey; Genge, Angela; De Silva, Shari; Zinman, Lorne; Chum, Marvin; Chio, Adriano; Sobue, Gen; Aoki, Masashi; Yoshino, Hiide; Doyu, Manabu; Selness, Daniel; Todorovic, Vesna; Sasson, Nissim; Hirai, Manabu; Takahashi, Fumihiro; Salah, Alejandro; Wamil, Art; Apple, Stephen
发表日期：2025
文献求助 收藏

Safety Extension Study of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis for up to an Additional 96 Weeks of Treatment

一项针对肌萎缩侧索硬化症患者的依达拉奉口服混悬液安全性扩展研究，疗程最长可达96周

期刊:Muscle & Nerve
影响因子:3.1
doi:10.1002/mus.28451
Genge, Angela; Pattee, Gary L; Sobue, Gen; Aoki, Masashi; Yoshino, Hiide; Couratier, Philippe; Lunetta, Christian; Petri, Susanne; Selness, Daniel; Todorovic, Vesna; Sasson, Nissim; Hirai, Manabu; Takahashi, Fumihiro; Salah, Alejandro; Apple, Stephen; Wamil, Art; Kalin, Alexander; Jackson, Carlayne E
发表日期：2025
文献求助 收藏

Analysis of Long-Term Function and Survival of Edaravone Oral Suspension-Treated Patients With Amyotrophic Lateral Sclerosis Using PRO-ACT Data as Historical Placebo Controls

利用 PRO-ACT 数据作为历史安慰剂对照，分析依达拉奉口服混悬液治疗肌萎缩侧索硬化症患者的长期功能和生存情况

期刊:Muscle & Nerve
影响因子:3.1
doi:10.1002/mus.28462
Takahashi, Fumihiro; Genge, Angela; Hirai, Manabu; Selness, Daniel; Todorovic, Vesna; Wamil, Art; Sasson, Nissim; Apple, Stephen; Ushirogawa, Yoshiteru
发表日期：2025
文献求助 收藏

Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment

口服依达拉奉在肌萎缩侧索硬化症患者中经过 48 周治疗后显示出良好的安全性。

期刊:Muscle & Nerve
影响因子:3.1
doi:10.1002/mus.27768
Genge, Angela; Pattee, Gary L; Sobue, Gen; Aoki, Masashi; Yoshino, Hiide; Couratier, Philippe; Lunetta, Christian; Petri, Susanne; Selness, Daniel; Bidani, Sachin; Hirai, Manabu; Sakata, Takeshi; Salah, Alejandro; Apple, Stephen; Wamil, Art; Kalin, Alexander; Jackson, Carlayne E
发表日期：2023
文献求助 收藏

Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals

选择性抑制 p38α MAPK-MK2 轴可抑制炎症信号，包括炎症小体启动信号

期刊:Journal of Experimental Medicine
影响因子:12.6
doi:10.1084/jem.20172063
Chun Wang, Susan Hockerman, E Jon Jacobsen, Yael Alippe, Shaun R Selness, Heidi R Hope, Jeffrey L Hirsch, Stephen J Mnich, Matthew J Saabye, William F Hood, Sheri L Bonar, Yousef Abu-Amer, Ariela Haimovich, Hal M Hoffman, Joseph B Monahan, Gabriel Mbalaviele
信号转导
MAPK/ERK
发表日期：2018
文献求助 收藏

Novel insights into the cellular mechanisms of the anti-inflammatory effects of NF-kappaB essential modulator binding domain peptides

对 NF-κB 必需调节剂结合域肽抗炎作用的细胞机制的新见解

期刊:Journal of Biological Chemistry
影响因子:4
doi:10.1074/jbc.M109.099895
Eric T Baima, Julia A Guzova, Sumathy Mathialagan, Eva E Nagiec, Medora M Hardy, Lily R Song, Sheri L Bonar, Robin A Weinberg, Shaun R Selness, Scott S Woodard, Jill Chrencik, William F Hood, John F Schindler, Nandini Kishore, Gabriel Mbalaviele
免疫
细胞生物学
其它细胞
NF-κB
发表日期：2010
文献求助 收藏

Expression, purification and functional characterization of IkappaB kinase-2 (IKK-2) mutants

IκB 激酶-2 (IKK-2) 突变体的表达、纯化和功能表征

期刊:Protein Expression and Purification
影响因子:1.4
doi:10.1016/j.pep.2010.02.009
Sumathy Mathialagan, Gennadiy I Poda, Ravi G Kurumbail, Shaun R Selness, Troii Hall, Beverly A Reitz, Robin A Weinberg, Nandini Kishore, Gabriel Mbalaviele
信号转导
发表日期：2010
文献求助 收藏

Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation

新型 N-苯基吡啶酮 p38 丝裂原活化蛋白激酶抑制剂的抗炎特性：临床前至临床的转化

期刊:Journal of Pharmacology and Experimental Therapeutics
影响因子:3.1
doi:10.1124/jpet.109.158329
Heidi R Hope, Gary D Anderson, Barry L Burnette, Robert P Compton, Rajesh V Devraj, Jeffrey L Hirsch, Robert H Keith, Xiong Li, Gabriel Mbalaviele, Dean M Messing, Matthew J Saabye, John F Schindler, Shaun R Selness, Loreen I Stillwell, Elizabeth G Webb, Jian Zhang, Joseph B Monahan
信号转导
p38 MAPK
发表日期：2009
文献求助 收藏

SD0006: a potent, selective and orally available inhibitor of p38 kinase

SD0006：一种强效、选择性、口服的 p38 激酶抑制剂

期刊:Pharmacology
影响因子:2.9
doi:10.1159/000227286
Barry L Burnette, Shaun Selness, Raj Devraj, Gail Jungbluth, Ravi Kurumbail, Loreen Stillwell, Gary Anderson, Stephen Mnich, Jeffrey Hirsch, Robert Compton, Pamela De Ciechi, Heidi Hope, Michael Hepperle, Robert H Keith, Win Naing, Huey Shieh, Joseph Portanova, Yan Zhang, Jian Zhang, Richard M Leimg
信号转导
p38 MAPK
Human
发表日期：2009
文献求助 收藏